- Reuters•1 hour ago
Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma. The Phase ...
- PR Newswire•9 days agoFavorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology
OSAKA, Japan, Sept. 18, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an exploratory analysis of the GEMINI 1 data, evaluating Entyvio (vedolizumab) therapy in patients with ulcerative colitis (UC) based on their treatment history with tumor necrosis factor (TNF) antagonists was published in Clinical Gastroenterology and Hepatology. The sub-group analysis, compared TNF-naïve with TNF-failure patients with moderately to severely active UC. The former had never received TNF antagonist therapy whilst those who had received and failed therapy due to inadequate response, loss of response or intolerance were in the latter group.
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||23.72 - 24.00|
|52wk Range||20.32 - 25.72|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||24.63|
|Avg Vol (3m)||37,312|
|Dividend & Yield||0.87 (3.68%)|